Krsnaa Diagnostics share price is back in focus as the diagnostics chain tries to build a base around the ₹527–₹570 zone after a sharp fall from its ₹850–₹900 highs. The company’s long-term growth story remains intact, with a 12% revenue CAGR over five years ahead of the broader diagnostics peer group, but FY26 numbers show a business that is still mid-way through a heavy investment cycle particularly in Rajasthan, where a ₹500 Cr PPP rollout is expected to become a meaningful revenue contributor only from FY27.
At the same time, a closer look shows rising debtor days (up from 48 to 163 over recent periods), sharply higher borrowings, and ROCE stuck around 12–13% against a management target of 15% all signs that the payoff from Krsnaa’s expansion hasn’t fully shown up in the numbers yet. The stock is now sitting right at a technical pivot, trying to defend support while a falling trendline still looms overhead.
So the natural question for investors searching Krsnaa Diagnostics share price today is:
Is the worst of the correction over and a genuine base forming, or is this just a pause before the stock resumes its downtrend?
In this article, we break down the company’s business, review its FY26 fundamentals, examine the technical chart, and assess whether Krsnaa Diagnostics share price deserves a spot on your watchlist.
Why Is Krsnaa Diagnostics Share Price in Focus?
Several developments have kept Krsnaa Diagnostics in the spotlight recently.
Key Investment Triggers
Rajasthan PPP Project Nearing Contribution Krsnaa is investing around ₹500 Cr in a Rajasthan PPP project covering CT/MRI expansion, pathology labs and collection centres, with management expecting meaningful contribution from Q4 FY27 and an annual revenue potential of roughly ₹100–200 Cr once ramped up.
Margins Holding Up Despite Expansion Costs Standalone operating margin has improved steadily from ~25% in FY24 to ~31% in FY26, even as new-centre costs from Rajasthan and Maharashtra are hitting profitability ahead of revenue.
Debtor Days Have Stretched Sharply Debtor days rose from 48 to as high as 163 over recent periods, though Q3 saw the company recover ₹130 Cr+ of government receivables, a sign collections are being actively addressed.
Rising Debt and Capex Borrowings jumped from around ₹202 Cr in FY25 to ₹531 Cr in FY26, alongside a sharp rise in capital work-in-progress (CWIP) from ₹3 Cr to ₹208 Cr, reflecting the scale of ongoing investment.
New Healthcare Optionality via Apulki Krsnaa has entered oncology and cardiac care through Apulki Healthcare, launching a 150-bed PPP cancer and cardiac hospital with Pune Municipal Corporation, with four more hospitals (~600 beds) approved.
Technical Base Formation On the weekly chart, the stock is consolidating between ₹527 support and ₹581 resistance after a sharp fall from its highs, with a falling trendline still capping any decisive move higher.
About Krsnaa Diagnostics Ltd
Krsnaa Diagnostics is one of India’s leading diagnostic chains, distinguished by its public-private partnership (PPP) model, where it partners with state governments to set up and operate diagnostic infrastructure rather than competing purely as a retail pathology brand.
Business Segments
Radiology (CT/MRI Centres)
Advanced diagnostic imaging through CT and MRI centres
Pathology Labs
Laboratory testing and diagnostic pathology services
Collection Centres
Diagnostic sample collection and patient access points
Retail/B2C Diagnostics
Direct-to-consumer diagnostic services and health testing
Apulki Healthcare
Oncology & Cardiac Care
Rather than being a conventional B2C diagnostics chain, Krsnaa’s core strength lies in long-duration government PPP contracts across 18 states/UTs, spanning around 190 CT/MRI centres, 140 pathology labs and 4,000+ collection centres a model that creates high entry barriers for competitors but also comes with the slower, delayed-payment cycle typical of government contracts.
Fundamental Analysis of Krsnaa Diagnostics
1. Sales Growth Good Long-Term Story, But Near-Term Growth Is Uneven
Krsnaa has delivered around 12% revenue CAGR over the last five years, ahead of the broader diagnostics peer group’s ~8%. FY26 standalone sales reached about ₹691 Cr, with consolidated FY26 revenue around ₹773 Cr. However, current growth doesn’t yet reflect the company’s future capacity, since Rajasthan and Maharashtra are still ramping up, with Rajasthan expected to start contributing meaningfully from Q4 FY27.
Investor Takeaway: The next 4–6 quarters matter far more than the historical growth numbers that’s when the new PPP projects should start showing up in revenue.
2. Business Outlook Rajasthan Is the Biggest FY27 Trigger
The Rajasthan PPP project, backed by around ₹500 Cr of investment, is Krsnaa’s biggest near-term growth opportunity, with management guiding for an annual revenue potential of roughly ₹100–200 Cr as it ramps up. Maharashtra radiology is another trigger, though MRI commissioning is still pending.
Investor Takeaway: Krsnaa has already made the heavy investment the real test now is whether these assets start generating revenue at the pace management expects.
3. Margins Are Strong, But Expansion Is Temporarily Hurting Profitability
Standalone operating margin improved from ~25% in FY24 to ~29% in FY25 to ~31% in FY26, and Q3 FY26 EBITDA margin held at around 26% despite additional employee, rent and Rajasthan rollout costs. The mismatch is timing-related new centres require staffing and infrastructure spend before patient volumes mature.
Investor Takeaway: If Rajasthan and Maharashtra ramp up as planned, operating leverage should kick in since the infrastructure is already built margins have room to improve rather than being under structural pressure.
4. Business Model and Competitive Moat PPP Is the Real Strength
Krsnaa’s PPP model, where it partners with governments to operate diagnostic infrastructure, creates a meaningful barrier to entry competitors need technology, equipment, government relationships and the ability to manage large-scale projects. Long-duration contracts, some with visibility extending up to decades, support strong revenue predictability.
Investor Takeaway: This structural moat is probably Krsnaa’s single biggest long-term advantage over conventional retail diagnostics chains.
5. Retail Business A Potential Second Growth Engine
Retail/B2C currently contributes roughly 8% of revenue, with management targeting 15–20% in FY27 and potentially 25–30% over the longer term. The company has expanded retail touchpoints rapidly to around 2,800–3,000+.
Investor Takeaway: A larger retail mix would reduce Krsnaa’s dependence on government contracts and could support a better valuation multiple if the shift plays out as guided.
6. Balance Sheet and Capex the Biggest Area to Monitor
Borrowings rose sharply from around ₹202 Cr in FY25 to ₹531 Cr in FY26, while CWIP jumped from just ₹3 Cr to ₹208 Cr, reflecting substantial ongoing investment. Free cash flow remains weak because investing expenditure is high, even as cash and bank balances have increased.
Investor Takeaway: The balance sheet isn’t a red flag by itself, but the combination of rising debt, heavy capex and a still-delayed revenue ramp-up is something investors need to track closely.
7. Working Capital Improving, but Still the Biggest Financial Concern
Debtor days rose sharply from 48 to 59 to 110 to 152 to 163 days a natural feature of government PPP contracts, but a meaningful amount of cash tied up nonetheless. The positive counterpoint is that Q3 saw the company recover over ₹130 Cr of government receivables, materially improving cash flow.
Investor Takeaway: This is a yellow-to-red flag rather than a permanent one a decline in debtor days toward management’s target would be a major positive trigger, while continued elevated days alongside rising debt would raise the risk further.
8. New Apulki Healthcare Business Interesting Long-Term Optionality
Krsnaa has entered the oncology and cardiac-care ecosystem through Apulki Healthcare, launching a 150-bed PPP cancer and cardiac hospital with Pune Municipal Corporation, with four more hospitals (~600 beds) already approved.
Investor Takeaway: This is a genuinely interesting long-term option but still an emerging business it shouldn’t be assigned significant valuation until it demonstrates revenue and profitability at scale.
9. Shareholding FII Buying Is Positive, but Promoter Holding Is Low
Promoter holding stands at around 27.1%, relatively low compared with many promoter-led Indian companies, though it has stayed broadly stable rather than showing continuous selling. FII holding rose from 3.91% to 4.28% between March and June 2026, and DII holding rose from 13.89% to 14.51% over the same period, while public holding remains above 54%.
Investor Takeaway: Rising institutional interest is a mildly encouraging sign, but with promoter ownership relatively low and public holding dominant, this is a shareholding structure worth continuing to monitor.
10. Biggest Red Flag and Overall Outlook
The core risk is the combination of high receivables, rising debt and heavy capex ahead of new centres reaching full utilization. ROCE currently stands at only around 12–13%, against a management target of approximately 15% an improvement that matters because a capital-intensive business must eventually earn an attractive return on the capital it has deployed.
Investor Takeaway: The investment case now hinges on execution whether Rajasthan and Maharashtra ramp up on schedule and whether ROCE moves meaningfully toward management’s target.
Key Positives
12% five-year revenue CAGR, ahead of the broader diagnostics peer group.
Operating margin has steadily improved from ~25% (FY24) to ~31% (FY26).
Strong structural moat via long-duration government PPP contracts across 18 states/UTs.
Retail business scaling up rapidly, targeting 15–20% of revenue in FY27.
₹130 Cr+ of government receivables recovered in Q3, showing active collections focus.
FII and DII holding both increased between March and June 2026.
Key Risks Investors Should Monitor
Debtor days rose sharply from 48 to as high as 163
Borrowings more than doubled from ~₹202 Cr to ~₹531 Cr in FY26
CWIP jumped from ₹3 Cr to ₹208 Cr, reflecting heavy ongoing capex
Free cash flow remains weak due to high investing expenditure
ROCE stuck around 12–13%, below management’s 15% target
Promoter holding relatively low at ~27.1%
Rajasthan and Maharashtra revenue ramp-up is not yet fully visible in the P&L
Technical Analysis of Krsnaa Diagnostics Share Price
From a technical standpoint, Krsnaa Diagnostics’ weekly chart shows a stock trying to stabilise after a sharp fall, with a genuine base-formation attempt underway but confirmation still pending.
A Base Is Forming Around ₹527–₹570
After falling sharply from the ₹850–₹900 zone, the stock has spent several weeks moving sideways, a sign that selling pressure has eased. The ₹527 zone has acted as an important support, with buyers actively defending this level.
₹527 Is the Level to Watch Closely
As long as the stock stays above ₹527 on a weekly closing basis, the current base remains intact. A decisive break below this level would put the entire bullish setup in question.
₹570–₹581 Is Where the Real Fight Is Happening
With the stock currently trading around ₹570, it sits just below the marked resistance at ₹580.95 the first important hurdle buyers need to clear with conviction, or the stock risks continuing to move sideways.
The Falling Trendline Still Matters
A trendline drawn from the stock’s previous high clearly shows a pattern of lower highs. Even if ₹581 is breached, that alone wouldn’t confirm the downtrend is over a genuine trendline breakout would offer much stronger confirmation.
Moving Averages Still Urge Caution
The stock remains below the major moving-average cluster around ₹658–₹665, indicating the larger trend hasn’t fully turned bullish yet. A sustained move above this cluster would meaningfully strengthen the technical picture.
RSI Is Comfortable
RSI sits around 45–46, neither overbought nor oversold, showing no major weakness at current levels. A break above ₹581 accompanied by RSI moving above 50–55 would support a genuine breakout.
Sellers Are No Longer Dominating
Price action near ₹527–₹570 shows the stock isn’t making fresh weekly lows instead it’s attempting to build a base, the kind of structure from which a reversal can develop, though confirmation from price action is still needed.
What Happens After ₹581 Breaks
If ₹581 breaks, the next battle is likely around ₹600–₹620, where the descending trendline comes into play clearing ₹581 alone shouldn’t be read as an all-clear signal. If the trendline itself breaks and the stock sustains above it, ₹658–₹665 becomes the bigger target zone, after which the broader technical structure would start looking meaningfully more positive.
Key Support Levels
| Support Level | Why It Matters |
|---|---|
| ₹527 | Important support; base-formation floor |
| ₹570 | Current pivot |
Key Resistance / Upside Targets
| Resistance / Target | Significance |
|---|---|
| ₹581 | First breakout trigger |
| ₹600–₹620 | Trendline test zone |
| ₹658–₹665 | Major resistance / moving-average zone |
| ₹735 | Next major resistance |
Should Investors Consider Krsnaa Diagnostics Share Price at Current Levels?
Krsnaa Diagnostics offers a genuinely strong structural story a PPP-driven moat, steadily improving margins, and a Rajasthan project that could become a meaningful FY27 growth trigger. The company’s move into retail diagnostics and the new Apulki Healthcare venture add further long-term optionality beyond its core PPP business.
At the same time, rising debtor days, sharply higher borrowings and heavy ongoing capex mean the payoff from this investment cycle hasn’t yet shown up in cash flow or ROCE. From a technical perspective, the stock is attempting to build a base between ₹527 and ₹581 after a steep fall, but with the broader trend still below its key moving averages, a decisive, volume-backed close above ₹581 followed by a genuine trendline breakout would be needed before the setup can be called constructive.
Final Thoughts
Krsnaa Diagnostics’ long-term thesis a defensible PPP moat, improving margins and a large Rajasthan opportunity remains intact, but FY26 was clearly a year of investment ahead of payoff. The real question for FY27 is whether Rajasthan and Maharashtra start converting into revenue as guided, and whether debtor days and ROCE improve alongside that ramp-up.
Investors would do well to track quarterly debtor-day trends, the pace of Rajasthan’s revenue contribution, and ROCE movement toward management’s 15% target, rather than judging the stock purely on its historical growth or the recent price correction. This is also where AI in investing is becoming genuinely useful stock market AI tools can track these specific execution metrics quarter after quarter, flagging shifts in receivables, capex intensity and margin trends as they happen, rather than requiring investors to piece the story together manually each time results are announced.
